established that empagliflozin administration did not significantly reduce colonic mTOR expression or inflammatory marker levels, in an experimental ulcerative colitis model [40], but we could argue that this can be attributed to the different regimen applied in their study, as the drug was administered for only one week. Here, MTOR is linked to ulcerative colitis.